Acquiring Company
BioNTech
Acquired Company
CureVac
MainzTübingenBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsDescription
BioNTech has finalized its acquisition of CureVac, with a tender offer completed on December 18, 2025. Approximately 86.75% of CureVac's shares were tendered, merging two leading mRNA firms in Germany. This acquisition enhances BioNTech’s intellectual property and production capabilities in mRNA technology. A squeeze-out for remaining shareholders of CureVac is expected in January 2026.
Who to call at BioNTech, and when
When BioNTech changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioNTech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioNTech, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioNTech makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired CureVac?
CureVac was acquired by BioNTech, based in Mainz. The deal was reported on December 20, 2025. BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases. BioNTech is publicly traded (BNTX) and operates in Biotechnology.
When did BioNTech acquire CureVac?
BioNTech's acquisition of CureVac was reported on December 20, 2025. BioNTech has finalized its acquisition of CureVac, with a tender offer completed on December 18, 2025. Approximately 86.75% of CureVac's shares were tendered, merging two leading mRNA firms in Germany. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does CureVac do?
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. It is privately held, operating in Biotechnology, and is based in Tübingen.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.